Fulgent's 20% Q2 Revenue Growth Looks Strong-Cash Flow Is the Real Test

Fulgent's Q2 growth was real, but cash flow is the harder signal

Strong top-line growth did not translate into a clean cash picture

Fulgent posted Q2 revenue of $85.4 million, up 20.1% sequentially. That is a strong growth print, but the more important question is whether the quarter reflected a healthier operating engine or simply a messier cash-conversion cycle. The available update points to consistent testing volumes alongside delays in claim processing and lower collection rates, which makes cash flow the more informative read for now.

The GAAP-to-non-GAAP gap is a reminder, not the main story

The margin spread is modest, but it still shows how much pressure the quarter absorbed. Fulgent reported GAAP gross margin of 30.1% versus Non-GAAP gross margin of 31.3%, while the loss picture remained wide at GAAP loss of $29.5 million, or $(1.05) per share versus Non-GAAP loss of $16.2 million, or $(0.58) per share. That does not imply manipulation, but it does mean investors should not confuse adjusted optics with clean execution.

Why collections matter more than the headline growth rate

Management has already linked the quarter's weaker cash conversion to a significant transition in the billing and revenue cycle management (RCM) system, and Full-year 2026 revenue guidance was revised downward to $330 million–$340 million. If reimbursement timing improves quickly, the quarter may look like a temporary bottleneck. If not, the market is likely to care less about the 20.1% sequential rise and more about whether revenue is converting into cash.

Fulgent grew through integration, but reimbursement friction slowed the payoff

Testing volume held even as collections lagged

Management said the quarter's revenue performance reflected the successful integration of Bako Diagnostics and StrataDX, enough to offset a $4.6 million decline from the company's largest customer. That suggests demand did not break across the platform.

The catch is that the same update said delays in claim processing and lower collection rates weighed on recognized revenue despite consistent testing volumes. In practical terms, that means the lab business still appeared active, but the billing pipeline became less efficient. Revenue can still show up while cash collection falls behind.

Acquisition benefits are real, but they do not erase operating friction

The strategic upside is not imaginary. Fulgent has doubled the sales team to approximately 40 members to cross-sell anatomic pathology and legacy services and broadened distribution by joining Epic's Aura platform. Those are concrete steps toward a more integrated diagnostic platform.

Still, the operating challenge remains visible. Management said Operational focus in the laboratory business is shifting toward digital pathology and AI integration to drive long-term efficiency, which reads less like a clean turnaround narrative and more like an in-progress buildout. The integration is progressing; the monetization timing is still the weaker link.

What would make FLGT more compelling from here

The bullish case depends on cleaner execution, not just growth

Fulgent remains interesting because the platform is expanding and the customer base did not collapse. The company has completed the successful integration of Bako Diagnostics and StrataDX, expanded sales coverage, and moved closer to health-system workflow integration through Epic's Aura platform.

But the more balanced takeaway is this: FLGT looks more like a watchlist name than a clear buy unless management can show that collections are stabilizing. The biggest risk is not weak demand by itself; it is persistent reimbursement friction that keeps cash flow weaker than revenue growth suggests.

What I would want to see in the next update

• A clear update on the billing and revenue cycle management (RCM) system transition and whether claim-processing delays are improving.
• Evidence that collection rates are recovering after the quarter's lower collection rates.
• Signs that the expanded platform is converting volume into better operating leverage, not just more complexity.
• Progress on the therapy pipeline, including updated FID-007 data at ASCO 2026 and any firm milestone timing toward a possible Phase 3 study.

My base case stays conditional. If Fulgent can turn consistent testing volume into cleaner billing and cash collection, the stock has a credible rerating path. If not, the story will keep looking more like a promising platform build than a fully proven cash-generation model.